Cargando…
Interim Clinical Treatment Considerations for Severe Manifestations of Mpox — United States, February 2023
Autores principales: | Rao, Agam K., Schrodt, Caroline A., Minhaj, Faisal S., Waltenburg, Michelle A., Cash-Goldwasser, Shama, Yu, Yon, Petersen, Brett W., Hutson, Christina, Damon, Inger K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Centers for Disease Control and Prevention
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9997665/ https://www.ncbi.nlm.nih.gov/pubmed/36862595 http://dx.doi.org/10.15585/mmwr.mm7209a4 |
Ejemplares similares
-
Tecovirimat Resistance in Mpox Patients, United States, 2022–2023
por: Smith, Todd G., et al.
Publicado: (2023) -
The CDC Domestic Mpox Response — United States, 2022–2023
por: McQuiston, Jennifer H., et al.
Publicado: (2023) -
Notes from the Field: Emergence of an Mpox Cluster Primarily Affecting Persons Previously Vaccinated Against Mpox — Chicago, Illinois, March 18–June 12, 2023
por: Faherty, Emily A. G., et al.
Publicado: (2023) -
Mpox respiratory transmission: the state of the evidence
por: Beeson, Amy, et al.
Publicado: (2023) -
Interim Estimates of 2022–23 Seasonal Influenza Vaccine Effectiveness — Wisconsin, October 2022–February 2023
por: McLean, Huong Q., et al.
Publicado: (2023)